Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 876 - 900 of 14411 in total
Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most...
Approved
Matched Description: … development of endocrine and autoimmune disorders, retinopathies, cardiovascular and neuropsychiatric ... 41% for genotype 1 and 75% for genotypes 2-6 after 48 weeks of treatment. ... the janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Intercellular Signaling Peptides and Proteins …
Avatrombopag (Doptelet), is an orally administered, small molecule thrombopoietin receptor (c-Mpl) agonist that increases platelet number without increasing platelet activation,[A33097,L2824] thereby decreasing the need for blood transfusions. Patients with thrombocytopenia and chronic liver disease often require platelet transfusions before surgical procedures to decrease the risk of bleeding. Thrombocytopenia is a...
Approved
Investigational
Matched Description: … [L2824] Patients with thrombocytopenia and chronic liver disease often require platelet transfusions …
Matched Categories: … Blood and Blood Forming Organs …
A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
Approved
Investigational
Matched Description: … A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol …
Rosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl). Like other thiazolidinediones, the mechanism of action of rosiglitazone is by activation of the intracellular receptor...
Approved
Investigational
Matched Description: … Rosiglitazone is a selective ligand of PPARγ, and has no PPARα-binding action. ... It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination ... resistance, it appears to have an anti-inflammatory effect: nuclear factor kappa-B (NFκB) levels fall and
Matched Categories: … Alimentary Tract and Metabolism ... metformin and rosiglitazone ... glimepiride and rosiglitazone …
Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.
Approved
Investigational
Matched Description: … It may cause diabetes mellitus, central nervous system damage, and other toxic effects. ... Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in …
Matched Categories: … Agents Against Leishmaniasis and Trypanosomiasis ... Antiparasitic Products, Insecticides and Repellents …
A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required. (From AMA Drug Evaluations Annual, 1994, p178)
Approved
Vet approved
A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604)
Approved
Investigational
Matched Description: … A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine …
Benzonatate is an oral antitussive drug used in the relief and suppression of cough in patients older than ten years of age. Currently, benzonatate is the only non-narcotic antitussive available as a prescription drug. It works to reduce the activity of cough reflex by desensitizing the tissues of the lungs...
Approved
Matched Description: … Benzonatate is an oral antitussive drug used in the relief and suppression of cough in patients older ... [A189519] It works to reduce the activity of cough reflex by desensitizing the tissues of the lungs and ... Although it not prone to drug misuse or abuse, benzonatate is associated with a risk for severe toxicity and
Matched Categories: … Cough and Cold Preparations …
Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment...
Approved
Investigational
Matched Description: … [T209] Lofexidine was developed by US Woldmeds LLC and it was approved by the FDA on May 16, 2018. ... Lofexidine was then repurposed for the treatment of opioid withdrawal, as it was seen to be more economical and
Fenofibrate is a fibric acid derivative like clofibrate and gemfibrozil. Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia.[L8588,L8591] Fenofibrate was granted FDA approval on 31 December 1993.
Approved
Matched Description: … Fenofibrate is a fibric acid derivative like [clofibrate] and [gemfibrozil]. …
Matched Categories: … pravastatin and fenofibrate ... simvastatin and fenofibrate ... rosuvastatin and fenofibrate ... pravastatin, ezetimibe and fenofibrate …
A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
Approved
Investigational
Matched Description: … It causes splenic vasodilation and may block autonomic ganglia. …
Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 January 2010 to treat a...
Approved
Matched Description: … [L40164] Subsequently, it was granted approval by Health Canada and the FDA in October [L43697] and December ... autoimmune disorders, such as different types of arthritis and cytokine release syndrome. ... [A193281] Tocilizumab was granted FDA approval on 8 January 2010 to treat a number of inflammatory and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Finerenone, or BAY 94-8862, is a mineralocorticoid receptor antagonist indicated to reduce the risk of sustained decline in glomerular filtration rate, end stage kidney disease, cardiovascular death, heart attacks, and hospitalization due to heart failure in adults with chronic kidney disease associated with type II diabetes mellitus.[A236519,L34739] Patients with kidney...
Approved
Investigational
Matched Description: … [A236544] Spironolactone has low selectivity and affinity for the receptor; it dissociates quickly and ... [A236544] Eplerenone is more selective and has longer lasting effects. ... can also have effects at the androgen, progesterone, and glucocorticoid receptors. …
A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States.
Approved
Vet approved
Matched Description: … It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Encorafenib, also known as BRAFTOVI, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion. Mutations in this gene,...
Approved
Investigational
Matched Description: … [L3344] On June 27, 2018, the Food and Drug Administration approved encorafenib and [binimetinib] ... role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Zucapsaicin, the cis-isomer of capsaicin, is a topical analgesic used to treat osteoarthritis of the knee and other neuropathic pain. It is a modulator of transient receptor potential cation channel subfamily V member 1 (TRPV-1), also known as the vanilloid or capsaicin receptor 1, that reduces pain and improves articular...
Approved
Investigational
Matched Description: … Zucapsaicin, the cis-isomer of capsaicin, is a topical analgesic used to treat osteoarthritis of the knee and ... subfamily V member 1 (TRPV-1), also known as the vanilloid or capsaicin receptor 1, that reduces pain and ... These conditions include herpes simplex (HSV) infections, cluster headaches, migraine, and osteoarthritis …
Matched Categories: … Capsaicin and Similar Agents ... Topical Products for Joint and Muscular Pain …
5-Hydroxytryptophan (5-HTP), also known as oxitriptan (INN), is a naturally occurring amino acid and metabolic intermediate in the synthesis of serotonin and melatonin. 5-HTP is sold over-the-counter in the United Kingdom, United States and Canada as a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid, and...
Approved
Investigational
Nutraceutical
Matched Description: … suppressant, and sleep aid, and is also marketed in many European countries for the indication of major ... 5-Hydroxytryptophan (5-HTP), also known as oxitriptan (INN), is a naturally occurring amino acid and ... metabolic intermediate in the synthesis of serotonin and melatonin. 5-HTP is sold over-the-counter in …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy. Netupitant is a neurokinin 1 receptor antagonist. The combination drug is marketed by Eisai...
Approved
Investigational
Matched Description: … The combination drug is marketed by Eisai Inc. and Helsinn Therapeutics (U.S.) ... approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and ... delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy …
Matched Categories: … Netupitant and prodrug …
Poloxamer 188 (P188) is a nonionic block linear copolymer that exhibits rheologic, anti-thrombotic, anti-inflammatory, and cytoprotective activities in various tissue injury models . Composed of two hydrophilic side-chains attached to a hydrophobic center core , its average molecular weight is 8400 Daltons. P188 was originally approved by the FDA in...
Approved
Investigational
Matched Description: … mouthwash, and used in various cosmetic, industrial and pharmaceutical applications. ... of _in vivo_ and _in vitro_ models [A27218]. ... ) is a nonionic block linear copolymer that exhibits rheologic, anti-thrombotic, anti-inflammatory, and
Novartis' brand name Zelnorm (tegaserod) had originally received approval from the US FDA in 2002 for the treatment of irritable bowel syndrome with constipation (IBS-C).[L5918,F4229] It was, however, voluntarily withdrawn from widespread use in the US market in 2007 after concerns arose over the possibility that tegaserod could potentially cause...
Approved
Investigational
Withdrawn
Matched Description: … the unique mechanism of action of acting on serotonin-4 (5-HT(4)) receptors in smooth muscle cells and ... the gastrointestinal wall to facilitate actions like esophageal relaxation, peristaltic gut movement, and ... re-approval' of tegaserod for treatment of IBS-C specifically in female patients less than 65 years of age and
Matched Categories: … Alimentary Tract and Metabolism …
Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ganglionic parasympathetic inhibitor. It has not been shown to be effective...
Approved
Matched Description: … It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. ... Mepenzolate diminishes gastric acid and pepsin secretion. …
Matched Categories: … Alimentary Tract and Metabolism …
Fostemsavir is the phosphonooxymethyl prodrug of temsavir, a novel HIV-1 attachment inhibitor. It binds to and inhibits the activity of gp120, a subunit within the HIV-1 gp160 envelope glycoprotein that facilitates the attachment of HIV-1 to host cell CD4 receptors - in doing so, temsavir prevents the first step in...
Approved
Investigational
Matched Description: … of gp120 as a potential target of interest in the treatment of HIV-1 infection is relatively recent, and ... [L14867,L14917] Targeting gp120 subunits is a new and novel therapeutic approach to HIV-1 infection, ... [L14867] It binds to and inhibits the activity of gp120, a subunit within the HIV-1 gp160 envelope glycoprotein …
Berdazimer is a polymeric substance consisting of a polysiloxane backbone (Si-O-Si bonds) with covalently bound N-diazeniumdiolate nitric oxide (NO) donors. It releases NO through exposure to proton donors like water, which will degrade the N-diazeniumdiolate entity. Berdazimer was previously investigated as a potential treatment for molluscum contagiosum, a viral cutaneous...
Approved
Matched Description: … skin discoloration, and fear and anxiety in the pediatric population. ... pediatric molluscum contagiosum, and it is the first drug to be approved for this condition. ... molluscum contagiosum, a viral cutaneous infection mainly affecting children, sexually active adults, and
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also...
Approved
Investigational
Matched Description: … in tumour cell proliferation and tumour angiogenesis. ... Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. ... It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. With a wide variety of applications and favourable safety profile, Botulinum toxin A injection is a minimally invasive and promising treatment for cosmetic...
Approved
Investigational
Matched Description: … is a minimally invasive and promising treatment for cosmetic imperfections, muscle spasms, and other ... [A231824] With a wide variety of applications and favourable safety profile, Botulinum toxin A injection ... [A231819,L32569] A popular use for Botox is the treatment of facial wrinkles and lines, however, there …
Matched Categories: … Enzymes and Coenzymes ... Amino Acids, Peptides, and Proteins …
Displaying drugs 876 - 900 of 14411 in total